AavantiBio Inc.

At least five biopharma companies have filed paperwork with the US Securities and Exchange Commission (SEC) since the start of 2024 to signal their intention to go public this year, entering what stil

Biopharmaceutical investors and executives alike conceded during the recent BIO International Convention that the booming financial environment, which peaked in 2020 and 2021 with record levels of ven

The biopharmaceutical industry cheered Third Harmonic Bio ’s sizeable initial public offering in mid-September but the IPO market in the US has gone quiet since then as broader stock indices – includ

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. BMS Calls On SyntheX, Autolus In Protei